NCCN Clinical Practice Guidelines in Oncology NCCN ...

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines?)

Non-Small Cell Lung

Cancer

Version 3.2020 ¡ª February 11, 2020



NCCN Guidelines for Patients?

Continue

Version 3.2020, 02/11/20 ? 2020 National Comprehensive Cancer Network? (NCCN?), All rights reserved. NCCN Guidelines? and this illustration may not be reproduced in any form without the express written permission of NCCN.

NCCN Guidelines Version 3.2020

Non-Small Cell Lung Cancer

*David S. Ettinger, MD/Chair ?

The Sidney Kimmel Comprehensive

Cancer Center at Johns Hopkins

NCCN Guidelines Index

Table of Contents

Discussion

Scott Gettinger, MD ? ?

Yale Cancer Center/Smilow Cancer Hospital

Gregory A. Otterson, MD ?

The Ohio State University Comprehensive

Cancer Center - James Cancer Hospital

and Solove Research Institute

Sandip P. Patel, MD ? ? ?

UC San Diego Moores Cancer Center

Dara L. Aisner, MD, PhD ¡Ù

University of Colorado Cancer Center

Ramaswamy Govindan, MD ?

Siteman Cancer Center at BarnesJewish Hospital and Washington

University School of Medicine

Gregory J. Riely, MD, PhD ? ?

Memorial Sloan Kettering Cancer Center

Wallace Akerley, MD ?

Huntsman Cancer Institute

at the University of Utah

Matthew A. Gubens, MD, MS ?

UCSF Helen Diller Family

Comprehensive Cancer Center

Steven E. Schild, MD ¡ì

Mayo Clinic Cancer Center

Jessica R. Bauman, MD ? ?

Fox Chase Cancer Center

Mark Hennon, MD ?

Roswell Park Comprehensive Cancer Center

Ankit Bharat, MD ?

Robert H. Lurie Comprehensive Cancer

Center of Northwestern University

Leora Horn, MD, MSc ?

Vanderbilt-Ingram Cancer Center

*Douglas E. Wood, MD/Vice Chair ?

Fred Hutchinson Cancer Research Center/

Seattle Cancer Care Alliance

Debora S. Bruno, MD, MS ?

Case Comprehensive Cancer Center/

University Hospitals Seidman Cancer

Center and Cleveland Clinic Taussig

Cancer Institute

Joe Y. Chang, MD, PhD ¡ì

The University of Texas

MD Anderson Cancer Center

Lucian R. Chirieac, MD ¡Ù

Dana-Farber/Brigham and Women¡¯s

Cancer Center

Thomas A. D¡¯Amico, MD ?

Duke Cancer Institute

Thomas J. Dilling, MD, MS ¡ì

Moffitt Cancer Center

NCCN

Kristina Gregory, RN, MSN, OCN

Miranda Hughes, PhD

NCCN Guidelines Panel Disclosures

Michael Dobelbower, MD, PhD ¡ì

O'Neal Comprehensive Cancer Center at UAB

Aditi P. Singh, MD ?

Abramson Cancer Center at the

University of Pennsylvania

Rudy P. Lackner, MD ?

Fred & Pamela Buffett Cancer Center

Michael Lanuti, MD ?

Massachusetts General Hospital Cancer Center

Ticiana A. Leal, MD ?

University of Wisconsin Carbone Cancer Center

Jules Lin, MD ?

University of Michigan Rogel Cancer Center

Billy W. Loo, Jr., MD, PhD ¡ì

Stanford Cancer Institute

Renato G. Martins, MD, MPH ?

Fred Hutchinson Cancer Research Center/

Seattle Cancer Care Alliance

Erminia Massarelli, MD ?

City of Hope National Medical Center

Continue

Theresa A. Shapiro, MD, PhD ? ?

The Sidney Kimmel Comprehensive

Cancer Center at Johns Hopkins

James Stevenson, MD ?

Case Comprehensive Cancer Center/

University Hospitals Seidman Cancer

Center and Cleveland Clinic Taussig

Cancer Institute

Alda Tam §æ

The University of Texas

MD Anderson Cancer Center

Kurt W. Tauer, MD ?

St. Jude Children¡¯s Research Hospital/

University of Tennessee Health Science Center

Stephen C. Yang, MD ?

The Sidney Kimmel Comprehensive

Cancer Center at Johns Hopkins

§æ Interventional radiology

? Hematology/Hematology

oncology

? Internal medicine

? Medical oncology

¡Ù Pathology

? Patient advocate

¡ì Radiation oncology/Radiotherapy

? Surgery/Surgical oncology

*Discussion Section Writing

Committee

Version 3.2020, 02/11/20 ? 2020 National Comprehensive Cancer Network? (NCCN?), All rights reserved. NCCN Guidelines? and this illustration may not be reproduced in any form without the express written permission of NCCN.

NCCN Guidelines Version 3.2020

Non-Small Cell Lung Cancer

NCCN Non-Small Cell Lung Cancer Panel Members

Summary of Guidelines Updates

Lung Cancer Prevention and Screening (PREV-1)

Clinical Presentation and Risk Assessment (DIAG-1)

Initial Evaluation and Clinical Stage (NSCL-1)

Evaluation and Treatment:

? Stage IA (T1abc, N0) (NSCL-2)

? Stage IB (peripheral T2a, N0), Stage I (central T1abc-T2a, N0),

Stage II (T1abc-2ab, N1; T2b, N0), Stage IIB (T3, N0), and Stage IIIA (T3, N1) (NSCL-3)

? Stage IIB (T3 invasion, N0) and Stage IIIA (T4 extension, N0-1; T3, N1; T4, N0-1) (NSCL-5)

? Stage IIIA (T1-2, N2); Stage IIIB (T3, N2); Separate Pulmonary Nodule(s) (Stage IIB, IIIA, IV) (NSCL-8)

? Multiple Lung Cancers (N0-1) (NSCL-11)

? Stage IIIB (T1-2, N3); Stage IIIC (T3, N3) (NSCL-12)

? Stage IIIB (T4, N2); Stage IIIC (T4, N3); Stage IVA, M1a: Pleural or Pericardial Effusion (NSCL-13)

? Stage IVA, M1b (NSCL-14)

Surveillance After Completion of Definitive Therapy (NSCL-16)

Therapy for Recurrence and Metastasis (NSCL-17)

Systemic Therapy for Advanced or Metastatic Disease (NSCL-18)

Principles of Pathologic Review (NSCL-A)

Principles of Surgical Therapy (NSCL-B)

Principles of Radiation Therapy (NSCL-C)

Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy (NSCL-D)

Chemotherapy Regimens Used with Radiation Therapy (NSCL-E)

Cancer Survivorship Care (NSCL-F)

Principles of Molecular and Biomarker Analysis (NSCL-G)

Emerging Biomarkers to Identify Novel Therapies for Patients with Metastatic NSCLC (NSCL-H)

Targeted Therapy for Advanced or Metastatic Disease (NSCL-I)

Systemic Therapy for Advanced or Metastatic Disease (NSCL-J)

Staging (ST-1)

NCCN Guidelines Index

Table of Contents

Discussion

Clinical Trials: NCCN believes that

the best management for any patient

with cancer is in a clinical trial.

Participation in clinical trials is

especially encouraged.

To find clinical trials online at NCCN

Member Institutions, click here:

clinical_trials/member_

institutions.aspx.

NCCN Categories of Evidence and

Consensus: All recommendations

are category 2A unless otherwise

indicated.

See NCCN Categories of Evidence

and Consensus.

NCCN Categories of Preference:

All recommendations are considered

appropriate.

See NCCN Categories of Preference.

The NCCN Guidelines? are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment.

Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical

circumstances to determine any patient¡¯s care or treatment. The National Comprehensive Cancer Network? (NCCN?) makes no representations or

warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN

Guidelines are copyrighted by National Comprehensive Cancer Network?. All rights reserved. The NCCN Guidelines and the illustrations herein may not

be reproduced in any form without the express written permission of NCCN. ?2020.

Version 3.2020, 02/11/20 ? 2020 National Comprehensive Cancer Network? (NCCN?), All rights reserved. NCCN Guidelines? and this illustration may not be reproduced in any form without the express written permission of NCCN.

NCCN Guidelines Version 3.2020

Non-Small Cell Lung Cancer

NCCN Guidelines Index

Table of Contents

Discussion

Updates in Version 3.2020 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 2.2020 include:

MS-1

? Discussion section updated based on the changes in the algorithm.

Updates in Version 2.2020 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 1.2020 include:

NSCL-19

? The following regimens added for the first-line treatment of patients with metastatic NSCLC and an EGFR mutation.

Erlotinib + ramucirumab as an "other recommended" treatment option as a category 2A.

Erlotinib + bevacizumab as a "useful in certain circumstances" treatment option as a category 2B.

NSCL-28

? The following treatment options added for patients with metastatic NSCLC, PD-L1 ¡Ý1%, and PS 0-2. (also applies to NSCL-29)

Carboplatin + albumin-bound paclitaxel + atezolizumab as an "other recommended" treatment option as a category 2A.

Nivolumab + ipilimumab as a "useful in certain circumstances" treatment option as a category 2A.

? Continuation Maintenance

Atezolizumab added as a treatment option, if atezolizumab/carboplatin/albumin-bound paclitaxel given.

NSCL-29 and NSCL-30

? Continuation Maintenance

Atezolizumab added as a treatment option, if atezolizumab/carboplatin/albumin-bound paclitaxel given.

NSCL-I 1 of 2 and NSCL-I 2 of 2

? Regimens and references added for combination therapies for metastatic NSCLC: erlotinib + ramucirumab, erlotinib + bevacizumab,

carboplatin + albumin-bound paclitaxel + atezolizumab, and nivolumab + ipilimumab.

NSCL-J 2 of 4

? The following treatment options added for patients with metastatic nonsquamous NSCLC, PD-L1 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download